Prostate Cancer Trial, Recruiting NCT07463092 Sponsor: University of Sao Paulo Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07463092
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men aged 40 years or older
  • People who have been diagnosed with localised prostate cancer confirmed by a tissue or cell sample test
  • People who have been receiving treatment to lower testosterone levels — either through surgical removal of the testicles or hormone-blocking medications — for at least six months before the trial starts
  • People who are currently on ongoing or periodic hormone therapy to reduce androgen (male hormone) levels
  • People who are well enough to carry out light to moderate daily activities, as assessed by a standard health performance scale (confirm with trial site)
  • People who have not done any resistance or strength training in the three months before the trial starts
  • People who have not used creatine supplements in the three months before the trial starts
  • People who are willing to take part in a 12-week program involving strength training three times per week and taking a daily supplement of either creatine monohydrate or a plain starch powder

Who may not be able to join:

  • People who have diabetes that requires insulin treatment
  • People whose kidneys have failed to the point of requiring dialysis
  • People with serious long-term liver disease
  • People whose kidneys are functioning at a significantly reduced level, based on a standard blood test measuring kidney filtration (confirm with trial site)
  • People who are receiving any hormone treatment that has not been prescribed or approved by their medical team
  • People who are planning to start chemotherapy within the next six months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Guilherme WP da Fonseca, PhD, School of Physical Education and Sport - USP

Phone: +55 11 3091 2137

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 December 2028

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Muscle Density (Ultrasound-derived Echo Intensity and Thickness)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov